吉非替尼治疗EGFR突变晚期肺腺癌的疗效与安全性研究  

Study on the efficacy and safety of gefitinib in the treatment of EGFR-mutant advanced lung adenocarcinoma

作　　者：谢馨[1] 陈康彪[1] 叶妍妍 黄康淼 XIE Xin;CHEN Kangbiao;YE Yanyan;HUANG Kangmiao(Guangdong Agricultural Reclamation Center Hospital,Guangdong,Zhanjiang 524002,China)

机构地区：[1]广东省农垦中心医院,广东湛江524002

出　　处：《中国医药科学》2020年第8期237-240,共4页China Medicine And Pharmacy

摘　　要：目的探究使用吉非替尼治疗表皮生长因子受体(EGFR)突变晚期肺腺癌的临床疗效和安全性。方法以2013年1月~2016年3月本院收治的EGFR突变晚期肺腺癌患者72例为研究对象,按照阳性突变位点的不同将之分为19号外显子缺失突变的19del组和21号外显子L858R突变的L858R组,分析吉非替尼治疗的临床疗效和安全性。结果L858R组疾病控制率、客观缓解率分别为92.86%、61.90%,19del组分别为100.00%、66.67%,两组疾病控制率、客观缓解率无显著差异且均处于较高水平(P>0.05);经吉非替尼治疗后患者总的无进展生存期和总生存期分别为(11.46±2.15)、(21.67±4.38)个月,并且发现19del组患者的无进展生存期、总生存期均显著长于L858R组(P<0.05);患者总的不良反应发生率为23.61%(17/72),以皮疹为主且症状均较轻,两组的不良反应发生率分别为23.81%和23.33%,差异无统计学意义(P>0.05)。结论使用吉非替尼对EGFR突变晚期肺腺癌进行治疗临床效果较好,可有效延长患者生存时间,并且具有较高的安全性。Objective To investigate the clinical efficacy and safety of gefitinib in the treatment of epidermal growth factor receptor(EGFR)-mutant advanced lung adenocarcinoma.Methods 72 patients with EGFR-mutant advanced lung adenocarcinoma admitted to our hospital from January 2013 to March 2016 were selected as the research subjects.The patients were divided into the 19del group with exon 19 deletion mutation and the L858R group with exon 21 L858R mutation according to the positive mutation sites.The clinical efficacy and safety of gefitinib were analyzed.Results The disease control rate and objective response rate of the L858R group were 92.86%and 61.90%,respectively,and those of the 19del group were 100.00%and 66.67%,respectively.There was no significant difference in the disease control rate and objective response rate between the two groups and both were at a high level(P>0.05).After gefitinib treatment,the progression-free survival and overall survival of all patients were(11.46±2.15)months and(21.67±4.38)months,respectively,and it was found that the progressionfree survival and overall survival of patients in the 19del group were significantly longer than those in the L858R group(P<0.05).The overall incidence of adverse reactions was 23.61%(17/72),which was mainly rash and the severity was mild.The incidences of adverse reactions in the two groups were 23.81%and 23.33%,respectively,without significant differences(P>0.05).Conclusion The use of gefitinib for the treatment of EGFR-mutant advanced lung adenocarcinoma has good clinical effects,which can effectively prolong the survival time of patients and shows high safety.

关 键 词：吉非替尼 表皮生长因子受体 肺腺癌 疗效 安全性 

分 类 号：R734.2[医药卫生—肿瘤]